A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Recruiting now · Phase 2/Phase 3
Conditions studied: Glioblastoma
In brief
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).
Key facts
- Study ID
- NCT03970447
- Run by
- Global Coalition for Adaptive Research
- People needed
- 2250
- Starts
- 2019-07-30
- Expected to finish
- 2030-06-01
- Last updated by the study team
- 2026-07-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Medical University of South Carolina - Hollings Cancer Center — Charleston, South Carolina, United States (enrolling)
- Royal Brisbane and Women's Hospital — Herston, Queensland, Australia (enrolling)
- Memorial Sloan Kettering Cancer Center* — New York, New York, United States (enrolling)
- University of Pittsburgh Medical Center - Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (enrolling)
- University of Utah - Huntsman Cancer Institute — Salt Lake City, Utah, United States (enrolling)
- Calvary Mater Newcastle — Waratah, New South Wales, Australia (enrolling)
- University of Colorado Denver — Aurora, Colorado, United States (enrolling)
- University of California, San Diego — La Jolla, California, United States (enrolling)
- Comprehensive Cancer Center of Wake Forest* — Winston-Salem, North Carolina, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California, United States (enrolling)
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- University of Virginia Health — Charlottesville, Virginia, United States (enrolling)
- Northern Sydney Cancer Centre/Royal North Shore Hospital — St Leonards, New South Wales, Australia (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Yale Cancer Center / Smilow Cancer Hospital* — New Haven, Connecticut, United States (enrolling)
- Allina Health Systems/Abbott Northwestern Hospital — Minneapolis, Minnesota, United States (enrolling)
- St. Joseph Hospital — Orange, California, United States (enrolling)
- University of Alabama at Birmingham — Birmingham, Alabama, United States (enrolling)
- Sylvester Comprehensive Cancer Center* — Miami, Florida, United States (enrolling)
- University Hospitals Cleveland Medical Center* — Cleveland, Ohio, United States (enrolling)
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
- Columbia University Medical Center — New York, New York, United States (enrolling)
- Flinders Medical Centre — Bedford Park, South Australia, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.